Showing posts with label diabetes. Show all posts
Showing posts with label diabetes. Show all posts

Monday, July 06, 2009

Recent estimates by the World Health Organization (WHO) calculate at least 171 million people worldwide suffer from diabetes and expect this figure to more than double, to reach 366 million, by 2030

According to Sanofi-Aventis SA, its long-acting Lantus [insulin glargine] drug didn't increase the risk of blindness for diabetics compared to an older type of insulin in a five-year study of more than 1,000 patients. In addition, there was...no 'observable trend' showing a difference in the risk of serious side effects including cancer, the drugmaker said in a statement.

"This 5-year study is the longest randomized controlled study with insulin glargine versus NPH human insulin," said lead investigator Julio Rosenstock, MD, Director of the Dallas Diabetes and Endocrine Center at Medical City and also Clinical Professor of Medicine, University of Texas Southwestern Medical Schoo.

The study results were published in the online edition of the Diabetologia medical journal.
Reblog this post [with Zemanta]

Tuesday, June 30, 2009

Experiment seeks to head off Type 1 diabetes

Researchers at Children's Hospital of Pittsburgh are hoping to control type 1 diabetes by curbing the rogue immune cells that cause it, before patients become completely dependent on daily insulin injections tosurvive.

About 3 million Americans have Type 1 diabetes, where the body mistakenly attacks and destroys cells in the pancreas that produce insulin, the hormone crucial to converting blood sugar to energy.

This novel vaccine -- made from patients' own blood blocks the '911 call' that dendritic cells send to direct T cells to the pancreas. Just altering three communication molecules on their surface basically confuses and paralyzes the T cells. In mice and monkeys, the reprogrammed cells ended the vicious cycle of a pancreas attack that in turn attracts more T cells to attack again.

In human trials, the team has used donated blood to filter out immature dendritic cells and then reprogram them. Animal experiments have shown that after the cells have been re-injected just inside the skin over the pancreas...the cells somehow find their way back to that organ to start working.

Two competing teams - MacroGenics Inc. and Eli Lilly, and Tolerx Inc. and GlaxoSmithKline - have advanced tests under way

Currently, 15 adult diabetics [are] being injected to make sure there are no unexpected side effects before researchers test if reprogrammed cells might really protect children's pancreas cells

Reblog this post [with Zemanta]

Thursday, December 11, 2008

Diabetes-related eye diseases may skyrocket over next four decades

The New York Times reports that, according to a study published Dec. 9 in the Archives of Ophthalmology, diabetes-related eye diseases will skyrocket over the next four decades, with elderly Hispanics and blacks hit hardest because of higher rates of Type 2 diabetes.

In particular, the report projects that the number of adults 40 and older with diabetic retinopathy -- the leading cause of blindness among working-age adults -- will reach 16 million in 2050, up from 5.5 million in 2005. In addition, the study estimates that the number of diabetics with glaucoma will quadruple to 1.4 million, while the number with cataracts will more than triple to 10 million. Study author Jinan B. Saaddine, M.D., M.P.H., of the Centers for Disease Control and Prevention (CDC), said the findings are a call for to do more to prevent diabetes to start with.

Thursday, October 16, 2008

Painkiller May Prevent Diabetes-Related Retinal Damage

The painkiller pentazocine may help prevent diabetes-related retinal damage that leads to vision loss, according to Medical College of Georgia researchers.

"The effects of this drug on retinal health are phenomenal," Dr. Sylvia Smith, a retinal cell biologist and co-director of the Vision Discovery Institute at MCG's School of Medicine, said in a college news release.

For the study, she compared the retinas of diabetic mice treated with pentazocine and those that didn't receive the drug and found dramatic differences. The findings suggest that the drug and related compounds that bind with the sigma receptor in the eye may help treat the two leading causes of vision loss -- diabetic retinopathy and glaucoma.

The study was published in the September issue of the journal Investigative Ophthalmology & Visual Science.

Twitter Delicious Facebook Digg Stumbleupon Favorites More

 
Design by Free WordPress Themes | Bloggerized by Lasantha - Premium Blogger Themes | Bluehost Review